MAPK3 and schizophrenia: This indicates that in schizophrenia and mood disorders, an under-stimulation of ERK1/2 signaling pathway may be involved in the symptomology of the disease, further supporting the notion that activation of the ERK1/2 pathway may be beneficial for treating neurological disorders.